NEU 0.00% $19.97 neuren pharmaceuticals limited

Ann: Completion of enrolment in Neuren's Angelman P2 trial, page-47

  1. 780 Posts.
    lightbulb Created with Sketch. 153
    You dont want lower limb weakness in a population with existing weakness and an elevated risk of falls. Bummer for Ultragenyx.
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.